Pittsburgh, PA, United States of America

Michelle Manni

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: University of Pittsburgh. Active years: 2015-2020.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michelle Manni: Innovator in Pulmonary Health

Introduction

Michelle Manni is a prominent inventor based in Pittsburgh, PA (US). She has made significant contributions to the field of pulmonary health through her innovative research and inventions. With a total of 2 patents, her work focuses on developing methods to prevent and treat pulmonary fibrosis.

Latest Patents

Michelle Manni's latest patents include a biologic scaffold for the prevention of pulmonary fibrosis. The methods provided in her patents involve delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of a subject. This approach is designed to effectively prevent, lessen, or treat pulmonary fibrosis. Additionally, her patents describe an apparatus for delivering the powdered ECM-derived material to a subject.

Career Highlights

Michelle Manni is affiliated with the University of Pittsburgh, where she conducts her research and development. Her work has garnered attention for its potential impact on improving respiratory health and addressing serious medical conditions.

Collaborations

Some of her notable coworkers include Tim D Oury and Thomas W Gilbert, who contribute to her research efforts and innovations in the field.

Conclusion

Michelle Manni's contributions to pulmonary health through her patents and research at the University of Pittsburgh highlight her role as an influential inventor. Her work continues to pave the way for advancements in the treatment of pulmonary fibrosis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…